Political Audit: Teva Pharmaceuticals

Corporate Communications & Public Stance

Three days after the 7 October 2023 attacks, Teva issued a statement titled “Standing with Israel,” describing the attacks as “unprecedented, horrific, and brutal” and affirming that “Teva stands with Israel in this time of great loss and challenge,” a statement that made no reference to Palestinian civilians and pivoted to business-continuity assurances noting Israel represents roughly 2% of global revenue and under 8% of global production ¹². During the May 2021 Gaza escalation, Teva joined a Globes-organized “coexistence” media campaign framed around domestic Israeli social cohesion, with no reference to Palestinian civilian harm ³. By contrast, in response to the 2022 Russian invasion of Ukraine, Teva issued a dedicated public statement and donated medicines valued at over $11 million (WAC), roughly 27 million doses, largely distributed via Direct Relief for Ukrainian refugees, while continuing sales into sanctioned Russia on stated humanitarian grounds, which drew separate press criticism ⁴⁵⁶. No public evidence identified. CEO Richard Francis told the Times of Israel in February 2024 that Teva’s Israeli operations had performed “extraordinary[ly]” through wartime conditions, asking rhetorically whether any other company “in a country that could have been part of a war” had performed similarly ². No public evidence identified of a Teva statement, press release, or executive comment addressing Palestinian civilian casualties, Gaza’s humanitarian conditions, or ICJ/ICC proceedings; the company’s only conflict-era public messaging identified in this audit is the pro-Israel 11 October 2023 statement and subsequent operational/financial commentary ¹².

Operations in Occupied or Contested Territories

Who Profits’ own company profile for Teva Pharmaceutical Industries, though dated to 2012, identifies no direct settlement facility operated by the company, focusing instead on market-structure critique ⁷. Historically, Teva-owned subsidiary MBT Biological Laboratories operated in the Atarot industrial zone in East Jerusalem/the West Bank before relocating to Beit Shemesh, a move reported by Haaretz in 2016 citing a Gush Shalom report and framed by that reporting as a possible response to boycott pressure, though the underlying relocation may have occurred years earlier ⁸. The most authoritative recent finding comes from KPMG Norway’s December 2024 “Targeted Research” report, commissioned by Norwegian hospital-procurement body Sykehusinnkjøp HF, which found “no presence, production, or other activity” by Teva in the occupied Palestinian territories and concluded there was no clear and unambiguous evidence that Teva benefits from Israel’s discriminatory trade policy toward Palestinians; Sykehusinnkjøp’s 2025 follow-up recommended not terminating contracts with Teva ⁹¹⁰¹¹. This contrasts with a 2012-dated Who Profits “Captive Economy” analysis, cited by AFSC Investigate and multiple boycott campaigns, alleging Teva benefits from tariff-free access to Palestinian markets under the Paris Protocol, non-Arabic product labeling, and reduced generic competition due to Israeli Ministry of Health restrictions on Palestinian producers ⁷¹². Campaign materials further assert that Teva medicines are distributed within West Bank settlements via Israeli HMOs (Clalit, Maccabi) and Megapharm-affiliated pharmacies, based on Google Maps store listings cited by campaign sources, representing downstream retail distribution via third parties rather than direct Teva settlement operations ¹³. A footwear retailer trading as “Teva Naot,” with stores reported in the Ariel and Kfar Etzion settlements, is a separate and unrelated Israeli company from Teva Pharmaceutical Industries Ltd., confirmed via distinct company-identifier and industry-classification records, and is flagged here only to prevent misattribution ¹⁴⁷. Within Israel proper (not occupied territory), an Iranian ballistic missile struck the Neot Hovav/Ramat Hovav industrial zone near Beersheba in 2026, near one of Teva’s largest active-pharmaceutical-ingredient plants, with Teva stating no material operational impact ¹⁵¹⁶. Civil-society and boycott campaigns targeting Teva over its Israel ties have escalated across multiple jurisdictions since 2019, including a Canadian BDS Coalition “Boycott TEVA” campaign, a worldwide “No Teva” campaign launched by Health Care Workers for Palestine and endorsed by the BDS Movement, UK protests outside a Teva facility in Castleford in March 2024, an Italian BDS-aligned campaign in Monza with a Monza council pharmacy notice in February 2026, over 50 pediatric consultants at Children’s Health Ireland requesting discontinuation of Teva procurement in August 2025, a September 2025 petition to the UN Global Compact seeking Teva’s removal, Europe-wide coordination reported by Peoples Dispatch in November 2025, and a healthcare boycott campaign in the Canary Islands in February 2026 ^{17131819202122}. Teva’s public responses to this pressure have consistently emphasized humanitarian and patient-access framing - citing risk to patient wellbeing and an approximately $226 million annual contribution to the Irish economy alongside more than €1.5 billion in a decade of NHS/HSE cost savings - rather than directly addressing the underlying political allegations ²⁰.

Internal Governance, Content & Retail Policies

No public evidence identified of Teva disciplining, suspending, or terminating any employee for pro-Palestinian speech, symbols, or union activity, across searches of boycott-campaign literature, labor-rights trackers, and general news. No public evidence identified of algorithmic moderation, content suppression, or editorial-policy controversy involving Teva, consistent with its status as a pharmaceutical manufacturer rather than a platform or media company. The only documented allegation regarding retail and supply-chain practices is the 2012-dated Who Profits claim that Teva products sold into the Palestinian market are not required to carry Arabic labeling, a condition attributed to the Paris Protocol trade regime rather than a Teva-specific policy choice, and which the December 2024 KPMG review did not substantiate as a discriminatory-benefit finding ⁷⁹. No public evidence identified of a formal shareholder resolution filed with Teva via SEC proxy/DEF 14A mechanisms specifically addressing Israel-Palestine human-rights due diligence; pressure on this front has instead taken the form of external NGO and consumer campaigns, including the Global Health BDS petition to the UN Global Compact and the Norwegian public-procurement review ²¹⁹¹⁰.

Brand Heritage & State Partnerships

No public evidence identified of Teva using military heritage, defense-sector ties, or state-security origins in its commercial branding or marketing. Teva hosted a series of recurring government and ceremonial engagements with Israeli state officials: Declassified UK’s reporting references a 2014 event at which then-UK PM David Cameron appeared alongside PM Netanyahu in connection with a Teva-NHS collaboration ²³; in October 2018 Teva formalized its North American headquarters relocation to New Jersey via a ceremony held at its Petach Tikva global headquarters in Israel, attended by NJ Governor Phil Murphy and Teva executives, with New Jersey granting $40 million in tax incentives ²⁴; in December 2017, PM Netanyahu, Finance Minister Kahlon, and Economy Minister Cohen met Teva’s CEO to request minimized layoffs and avoid closing the Jerusalem plant, a request Teva declined to fully accommodate though some delays followed ²⁵²⁶; and in November 2020, PM Netanyahu and Health Minister Yuli Edelstein visited Teva’s ultra-cold-chain logistics site immediately ahead of Israel’s first Pfizer COVID-19 vaccine deliveries, for which Teva served as the state’s exclusive in-country distribution partner ²⁷²⁸. No public evidence identified of formal Teva sponsorship of an explicit “Brand Israel” public-diplomacy campaign or of other academic/state institutional partnership programs.

Lobbying, Advocacy, Financing & Logistics

Teva Pharmaceutical Industries reported US federal lobbying expenditures of $3,930,000 in 2021, $3,910,000 in 2022, and $2,250,000 in 2024, with its federal PAC (FEC ID C00434811) contributing $72,400 to candidates in the 2021–2022 cycle and $108,729 in the 2024 cycle, with disclosed issues concerning pharmaceutical pricing, IP, and health legislation rather than Israel/Palestine policy ²⁹³⁰. Teva Pharmaceuticals Europe BV declared a 2025 EU lobbying budget of €600,000–€699,999 with roughly two Brussels-based FTE staff, and eight documented high-level European Commission meetings between 2019 and 2026 addressed pharmaceutical and health-policy topics such as supply-chain resilience and generics capacity, none of which were Israel/Palestine-related ³¹. No public evidence identified of Teva or its executives holding leadership roles in CFI, AIPAC, ADL, USISTF, or similar advocacy bodies, or of corporate anti-BDS lobbying activity. Teva participated in the IDF-linked “Adopt-a-Battalion” reservist-welfare program, under which participants reportedly commit roughly 100,000 NIS (~$27,000) annually for three years, though Teva is no longer listed as an active partner on the program’s current website and the discontinuation date is unclear ³²³³³⁴. Collection points at five Teva Israel sites gathered approximately 1.5 tons of equipment donated by employees to the IDF by the end of October 2023 ³². “Thank Israeli Soldiers,” an organization operating “in coordination with the IDF,” stated in June 2024 that “Teva has funded professional supervision for our facilitators” ²³. Teva funded training for roughly 200 therapists, targeted for completion by February 2024, through its “Support the Soul” program in partnership with Momentum, an organization supporting IDF combat-soldier mental health ². No public evidence identified of direct Teva corporate donations to FIDF, JNF/KKL, Lev Echad, Regavim, or Im Tirtzu. During the COVID-19 pandemic, Teva/Teva-SLE served as the Israeli government’s exclusive logistics and distribution partner for the national vaccine rollout, including ultra-cold-chain storage and transport to roughly 400 vaccination sites via infrastructure at Shoham and Kfar Saba ²⁷. In the opening weeks of the current conflict, Teva employees were redirected to distribution centers to manage a threefold medication-demand surge, logging over 7,000 volunteer hours ². Teva-donated medicines have been included in Direct Relief’s humanitarian shipments into Gaza, including a May 2024 delivery and further shipments totaling 5.9 tons by January 2026 and 15.9 tons by May 2026 alongside other manufacturers’ donations ³⁵³⁶³⁷.

Corporate Structure & Primary Mission

Teva is publicly traded on the NYSE and Tel Aviv Stock Exchange, with institutional ownership reported at approximately 62.6% as of April 2025, led by Capital Research Global Investors (~11.2%) and BlackRock (~8.7%) per secondary financial analysis; that same analysis describes a conventional one-share-one-vote structure with no golden share, special Israeli-government voting rights, or state equity stake identified ³⁸. No public evidence identified of a primary SEC filing directly confirming this ownership-structure characterization, as the finding rests on a secondary financial-analysis source rather than a directly fetched 20-F or Articles of Association. In June 2024, Teva agreed to pay $750 million in installments between 2024 and 2029 to resolve a dispute with Israel’s Tax Authority covering taxable years 2008–2020, plus a contingent additional payment of 5–7% of future dividends/buybacks capped at approximately $500 million ³⁹⁴⁰. A separate campaign-sourced claim cites a $721 million 2024 contribution to the Israeli treasury attributed to “SEC filings,” but this figure was not independently verified against a primary SEC document in this audit and should be treated as unconfirmed ³².

Executive & Leadership Footprint

CEO Richard D. Francis, in role since January 2023, has been characterized by campaign sources as a public “voice of Israel” during the current conflict, consistent with his on-record Times of Israel comments emphasizing Israel’s strategic centrality to Teva and praising Israeli staff’s wartime performance ^4121332. Hadar Mama, director of Teva-owned logistics subsidiary SLE - reported by the Jerusalem Post as the sole authorized distributor of medication to the Palestinian territories under the relevant regulatory arrangement - served as an active IDF reservist in the Gaza Strip in December 2023 while continuing in his corporate leadership role, a dual role campaign sources have characterized as a documented conflict-of-interest concern to which no company response was located ³². Chairman Dr. Sol J. Barer, chairman since 2017 and reelected through a term extending to 2029 per the FY2026 proxy statement, has a career background in US biotech and pharma (Celgene), with no Israel-military or settlement-organization affiliation identified in searches conducted ⁴². Former CEO Shlomo Yanai, whose tenure ran from 2007 to 2012 and predates the current audit period, was a retired IDF Major General who held senior IDF command roles - including Head of the Planning Branch (1998–2001) and GOC Southern Command (1996–1998) - before his Teva presidency, a historical data point relevant to founding-era institutional culture rather than current conduct ²⁹. No public evidence identified connecting any current Teva board member or executive to Unit 8200 or other IDF intelligence-unit service, across SEC proxy filings, general news, and executive-profile databases. No public evidence identified of personal (as opposed to corporate) donations by Francis, Barer, or other current named executives to FIDF, JNF/KKL, or settlement organizations.

End Notes